The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry

The antifibrotic drug nintedanib is used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the effect of nintedanib on antifibrotic treatment outcome in real-world cohorts of Czech EMPIRE registry. Data of 611 Czech IPF subjects, 430 (70%) treated with nintedanib (NIN group), 181...

Full description

Saved in:

Bibliographic Details
Published in:	BMC pulmonary medicine Vol. 23; no. 1; p. 154
Main Authors:	Štefániková, Marianna, Doubková, Martina, Ovesná, Petra, Šterclová, Martina, Lacina, Ladislav, Žurková, Monika, Plačková, Martina, Bartoš, Vladimír, Janíčková, Ivana, Bittenglová, Radka, Anton, Jan, Sýkorová, Ľubica, Lošťáková, Vladimíra, Musilová, Pavlína, Šuldová, Hana, Mokošová, Radka, Didyk, Jurij, Šišáková, Lenka, Lisá, Pavlína, Lněnička, Jaroslav, Dařičková, Hana, Doležel, Daniel, Pšikalová, Jana, Tyl, Richard, Králová, Renata, Vašáková, Martina Koziar
Format:	Journal Article
Language:	English
Published:	England BioMed Central Ltd 03-05-2023 BioMed Central BMC
Subjects:	Age Analysis Carbon monoxide Czech Republic Drug therapy Emphysema Fibrosis Forecasts and trends Growth factors Humans Idiopathic pulmonary fibrosis Idiopathic Pulmonary Fibrosis - drug therapy Lung Lung diseases Lung function decline Medical prognosis Mortality Nintedanib Overall survival Patients Physiology Pneumonia Prevention Pulmonary fibrosis Pulmonary function tests Pulmonology Registries Respiratory function Survival Treatment Outcome Vital Capacity Czech Republic Nintedanib Overall survival Lung function decline Idiopathic pulmonary fibrosis
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The antifibrotic drug nintedanib is used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the effect of nintedanib on antifibrotic treatment outcome in real-world cohorts of Czech EMPIRE registry. Data of 611 Czech IPF subjects, 430 (70%) treated with nintedanib (NIN group), 181 (30%) with no-antifibrotic treatment (NAF group) were analysed. The influence of nintedanib on overall survival (OS), pulmonary function parameters as forced vital capacity (FVC) and diffusing lung capacity for carbon monoxide (DLCO), as well as GAP score (gender, age, physiology) and and CPI (composite physiological index) were investigated. During 2 year follow-up we observed that nintedanib treated patients had longer OS, compared to those treated with no-antifibrotic drugs (p < 0.00001). Nintedanib reduces risk of mortality over no-antifibrotic treatment by 55% (p < 0.001). We have observed no significant difference in the rate of FVC and DLCO decline between the NIN and NAF group. Changes within 24 months from baseline in CPI were not significant between the groups (NAF and NIN). Our real-practice study showed the benefit of nintedanib treatment on survival. There were no significant differences between NIN and NAF groups in changes from baseline in FVC %, DLCO % predicted and CPI.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1471-2466 1471-2466
DOI:	10.1186/s12890-023-02450-3